KNSA(Kiniksa Pharmaceuticals International, plc) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $38.54M | $220.18M | $270.26M | $423.24M | $677.56M |
| 毛利润 | $29.44M | $197.28M | $236.85M | $362.33M | $599.89M |
| 营业利润 | −$156.64M | $9.77M | −$25.20M | −$45.62M | $77.22M |
| 净利润 | −$157.92M | $183.36M | $14.08M | −$43.19M | $59.01M |
| 经营现金流 | −$126.30M | $5.81M | $13.30M | $25.69M | $137.99M |
| 自由现金流 | −$126.71M | $5.70M | $13.17M | $25.41M | $136.42M |
| 摊薄每股收益 | $-2.30 | $2.60 | $0.20 | $-0.60 | $0.75 |